Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityGlobeNewsWire · 4 days ago
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to BrokeragesDefense World · Oct 12, 2026
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology ConferencesGlobeNewsWire · Sep 30, 2026
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology ConferencesGlobeNewsWire · Sep 10, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 8, 2026
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027GlobeNewsWire · Aug 27, 2026Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.39 | -$0.62 | Miss |
| May 12, 2026 | -$0.59 | -$0.41 | Beat |
| Mar 11, 2026 | -$0.43 | -$0.51 | Miss |
| Nov 14, 2025 | -$1.14 | -$0.03 | Beat |
| Aug 12, 2025 | -$0.70 | $0.02 | Beat |
| May 13, 2025 | -$1.23 | -$1.00 | Beat |